ARVN earnings analysis
What we found in ARVN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Arvinas reported a large Q2 profit and revenue surge, with $249.7 million of revenue and $2.58 diluted EPS, but the result was driven principally by deferred-revenue release, the Rigel license and the $50.0 million VEPPANU approval milestone rather than recurring product sales. Cost reductions lowered Q2 R&D to $52.6 million and improved six-month operating cash use to $117.5 million, while liquidity of $567.9 million is expected to fund operations into H2 2028. The outlook is balanced by a clinical hold on ARV-102 in PSP and heightened dependence on Rigel to commercialize the company's only approved product.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Collaboration revenue drove major Q2 beat
- Q2 revenue was $249.7 million, up $227.3 million from $22.4 million a year earlier and $233.7 million from $16.0 million in Q1 2026. The increase reflected $112.6 million from the Pfizer collaboration, $62.5 million from the Rigel license, and a $50.0 million VEPPANU approval milestone.
- Profitability turned sharply positive
- Net income was $169.4 million, versus a $61.2 million net loss in Q2 2025; diluted EPS was $2.58 versus a $0.84 loss a year ago and a $0.90 loss in Q1 2026. Calculated operating margin reached 65.7%, compared with a 319.2% operating loss margin a year ago.
- Cost actions reduced operating spend
- R&D expense declined $16.0 million year over year to $52.6 million, while G&A fell $1.3 million to $24.0 million. R&D personnel expense fell $11.0 million, partly offset by higher ARV-806, ARV-027 and ARV-393 external spend of $3.9 million, $3.2 million and $2.3 million, respectively.
- VEPPANU approval creates licensing optionality
- The FDA approved VEPPANU in Q2 2026, and the Rigel agreement provides an aggregate $70.0 million upfront payment, a further $15.0 million upon transition activities, and up to $320.0 million in development, regulatory and commercial milestones, all shared equally with Pfizer.
- Cash runway extends into H2 2028
- Liquidity remained substantial at $567.9 million at June 30, 2026, although down $117.5 million from $685.4 million at December 31, 2025. Management believes this cash runway supports operations into the second half of 2028; debt was only $0.5 million.
- Multiple near-term pipeline milestones
- Pipeline catalysts are scheduled for the second half of 2026: ARV-393 early monotherapy data and ARV-806 Phase 1 dose-escalation data. ARV-6723 is expected to enter Phase 1 in Q3 2026.
- Operating cash burn improved year over year
- Six-month operating cash use improved to $117.5 million from $184.3 million a year earlier. Capital expenditures were not separately disclosed, so free cash flow and capex intensity cannot be calculated from the filing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Q2 earnings rely on one-time revenue recognition
- The $249.7 million quarter was largely nonrecurring license/collaboration recognition, including $126.4 million of remaining Pfizer deferred revenue, $62.5 million from the Rigel agreement and a $50.0 million FDA-approval milestone. Arvinas states it does not expect product-sales revenue in the near future, if ever.
- VEPPANU economics now depend on Rigel
- The amended risk factor makes Rigel solely responsible for VEPPANU commercialization and key decisions. Arvinas and Pfizer may receive up to $320.0 million in contingent Rigel milestones, but payment and any sales-derived economics depend on Rigel's performance.
- ARV-102 PSP program is on FDA clinical hold
- The ARV-102 PSP Phase 1b has not dosed patients and is on clinical hold after the FDA requested additional information and final chronic toxicology data following its 30-day review. Subject to clearance, management now plans to initiate PSP trials in 2027.
- Cash burn continues despite extended runway
- Cash, cash equivalents and marketable securities declined $117.5 million in six months to $567.9 million, while operating cash flow was negative $117.5 million. Management expects to need substantial additional financing despite its second-half 2028 runway estimate.
- New AI governance and cybersecurity risk
- A new risk factor identifies AI and machine-learning exposure in discovery operations, including data leakage, model poisoning, IP, privacy and regulatory risks. The EU AI Act, which entered into force on August 1, 2024, is expected to become largely effective in August 2026.
- Research collaboration base is narrowing
- Genentech gave termination notice on June 9, 2026, and the collaboration will terminate effective August 8, 2026. The Pfizer research-program term has also concluded, reducing the pool of active research collaborations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $2.58
- Gross margin
- 96.4%
- Operating margin
- 65.7%
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the 10-Q. Management expects $567.9 million of cash, cash equivalents and marketable securities at June 30, 2026 to fund planned operating expenses and capital expenditures into the second half of 2028.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Arvinas reported a dramatic decline in revenue for Q1 2026, with total revenue falling to $15.6 million from $188.8 million in Q1 2025. The company experienced a net loss of $57.6 million, compared to a net income of…
- 10-K · February 24, 2026
- Arvinas positions itself as a clinical‑stage PROTAC platform company focused on oncology and neurology, highlighting an accepted NDA for vepdegestrant with a PDUFA date of June 5, 2026 and multiple clinical programs…
- 10-Q · August 6, 2025
- Arvinas reported Q2 revenue of $22.4 million, down sharply from $76.5 million in Q2 2024, and posted an operating loss of $71.5 million (versus $48.5 million a year ago). Diluted EPS was a loss of $0.84 compared with a…
- 10-Q · May 1, 2025
- Arvinas reported a large, one-time-driven revenue and profit swing in Q1 2025: revenue was $188.8M and GAAP net income $82.9M (EPS $1.14), versus revenue $25.3M and net loss $(69.4)M (EPS $(0.97)) in Q1 2024. The result…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ARVN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever